For a healthy perimenopausal woman with an intact uterus, how long should transdermal estradiol be used with daily oral micronized progesterone, and should the progesterone be taken every other day?

Hormone Therapy Regimen for Perimenopausal Women

For a healthy perimenopausal woman with an intact uterus using transdermal estradiol, oral micronized progesterone should be taken daily at 200 mg for 12-14 consecutive days every 28-day cycle—not every other day—and this regimen should be continued until the average age of natural menopause (45-55 years). 1, 2

Dosing Schedule

The FDA-approved and guideline-supported regimen is clear:

• Transdermal estradiol: Apply continuously (daily) without interruption
• Oral micronized progesterone: 200 mg daily for 12-14 days per 28-day cycle 1, 2
• Timing: Take progesterone at bedtime due to potential drowsiness, dizziness, or blurred vision 2

Do not use progesterone every other day. This dosing frequency is not supported by evidence for endometrial protection and would likely be inadequate 3.

Duration of Therapy

Continue this regimen until age 45-55 years (average age of spontaneous menopause). 1 After reaching this age range, reassess whether to continue based on:

• Individual cardiovascular and thrombotic risk factors
• Family history of hormone-sensitive cancers
• Severity of ongoing menopausal symptoms
• Patient preference regarding quality of life

The evidence shows that hormone therapy in cancer survivors with premature ovarian insufficiency should continue until natural menopause age, and this principle applies to perimenopausal women requiring endometrial protection 1.

Why This Specific Regimen

Micronized progesterone is the preferred progestogen because it demonstrates:

• Lower cardiovascular disease risk compared to synthetic progestins 1
• Lower venous thromboembolism risk 1
• Adequate endometrial protection when used 12-14 days per cycle at 200 mg daily 3

The sequential (cyclical) approach—estrogen continuously with progesterone for 12-14 days monthly—provides endometrial protection while allowing withdrawal bleeding 1. Clinical trial data confirms that 200 mg daily oral micronized progesterone for 12 days per 28-day cycle reduces endometrial hyperplasia incidence to 6% (compared to 64% with estrogen alone) 2.

Alternative Regimens (If Needed)

If the patient wishes to avoid withdrawal bleeding, consider:

• Continuous combined therapy: Transdermal estradiol daily plus continuous oral progesterone (requires higher daily doses: minimum 100 mg daily, though evidence for this dose is limited) 1
• Combined patches: Estradiol + levonorgestrel patches applied continuously 1

However, the sequential regimen with 200 mg progesterone for 12-14 days has the strongest evidence base for endometrial protection over extended periods (up to 5 years documented) 3.

Critical Pitfalls to Avoid

• Never use progesterone every other day: This frequency lacks evidence for adequate endometrial protection
• Don't stop therapy prematurely: Women with intact uteri on estrogen therapy require progestogen protection until natural menopause age
• Don't use transdermal progesterone: It does not provide endometrial protection 3
• Avoid taking progesterone with food or while lying down: Take at bedtime with water while standing to minimize side effects and improve absorption 2

Monitoring Requirements

• Annual pelvic examination and breast evaluation
• Investigate any unusual vaginal bleeding immediately (may indicate inadequate endometrial protection or other pathology) 2
• Reassess need for continued therapy annually, particularly after age 51 years